How many drugs treat Nausea and vomiting?

Drug Landscape tracks 8 marketed treatments for Nausea and vomiting (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nausea-and-vomiting.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nausea and vomiting — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nausea and vomiting (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nausea and vomiting, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Motilium	domperidone	Johnson & Johnson (Janssen)	Prokinetic agent / Antiemetic	Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2	1978-01-01
Dimenhydrinate	DIMENHYDRINATE	Alra	dimenhydrinate	Histamine H1 receptor	1972-01-01
Ethylthioperazine	THIETHYLPERAZINE	Novartis	thiethylperazine	Alpha-1A adrenergic receptor	1961-01-01
Compazine	PROCHLORPERAZINE	GSK	Phenothiazine	D(2) dopamine receptor	1956-01-01
Thorazine	chlorpromazine	Generic (originally Rhône-Poulenc/Sanofi)	Typical antipsychotic (first-generation, phenothiazine)	Aldehyde oxidase, Sphingomyelin phosphodiesterase, 5-hydroxytryptamine receptor 1E	1954-03-26
Phenergan	promethazine	Generic (originally Wyeth/Pfizer)	Phenothiazine antihistamine/antiemetic	Aldehyde oxidase, 5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR	1951-01-01
Domperidon	Domperidon	Gadjah Mada University		Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2
Motilium	Motilium	Rabin Medical Center		Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Nausea and vomiting
Alra · 1 drug in Nausea and vomiting
GSK · 1 drug in Nausea and vomiting
Gadjah Mada University · 1 drug in Nausea and vomiting
Generic (originally Rhône-Poulenc/Sanofi) · 1 drug in Nausea and vomiting
Generic (originally Wyeth/Pfizer) · 1 drug in Nausea and vomiting
Johnson & Johnson (Janssen) · 1 drug in Nausea and vomiting
Novartis · 1 drug in Nausea and vomiting
Rabin Medical Center · 1 drug in Nausea and vomiting

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nausea and vomiting:

Cite this brief

Drug Landscape (2026). Nausea and vomiting — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nausea-and-vomiting. Accessed 2026-06-10.

Nausea and vomiting full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing